Watchlist Price Alert

Repligen Corporation (RGEN)

NASDAQ: RGEN · Real-Time Price · USD

141.52

4.32 (3.15%)

At close: May 02, 2025, 3:59 PM

141.51

-0.01%

After-hours: May 02, 2025, 04:30 PM EDT

3.15% (1D)

Bid	134.5
Market Cap	7.95B
Revenue (ttm)	645.66M
Net Income (ttm)	-25.37M
EPS (ttm)	-0.41
PE Ratio (ttm)	-345.17
Forward PE	61.07
Analyst	Buy

Ask	150
Volume	471,198
Avg. Volume (20D)	797,420
Open	140.52
Previous Close	137.20
Day's Range	138.76 - 142.66
52-Week Range	102.97 - 182.52
Beta	1.27

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used i...

Sector Healthcare

IPO Date Apr 29, 1986

Employees 1,778

Stock Exchange NASDAQ

Ticker Symbol RGEN

Website https://www.repligen.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is $180, which is an increase of 27.19% from the latest price.

Stock Forecasts

Earnings Surprise

Repligen has released their quartely earnings on Apr 29, 2025:

Revenue of $169.17M exceeds estimates by $5.42M, with 11.78% YoY growth.

EPS of 0.39 exceeds estimates by 0.04, with 39.29% YoY growth.

Why Price Moved

1 month ago

-5.54%

Repligen shares are trading lower. Evercore ISI Gr... Unlock content with Pro Subscription

2 months ago

+7.92%

Repligen shares are trading higher after the company reported better-than-expected Q4 financial results

News

2 days ago · zacks.com

QGEN or RGEN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to v...

3 days ago · zacks.com

Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y

RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.

5 days ago · seekingalpha.com

Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript

Repligen Corporation (NASDAQ:RGEN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Jacob Johnson - VP, IR Olivier Loeillot - President, CEO & Director Jason Garland - ...

5 days ago · zacks.com

Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates

Repligen (RGEN) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.28 per share a year ago.

1 week ago · zacks.com

Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?

Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 week ago · zacks.com

Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth

Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · zacks.com

GMAB or RGEN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value...

3 weeks ago · zacks.com

Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?

Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro...

1 month ago · seekingalpha.com

Repligen: Ongoing Bioprocessing Market Recovery

I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in no...

2 months ago · benzinga.com

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

On Tuesday, Repligen Corporation RGEN purchased 908 Devices Inc.'s MASS desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.

Load More News